GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide are being adopted at an unprecedented pace worldwide as pharmacologic tools for weight management. While much of the existing research has focused on their long-term effects on weight loss and obesity-related complications such as cardiometabolic disease, cardiovascular outcomes, and renal disease, less attention has been paid to how these agents may influence everyday consumer behavior. A recent U.S. study explored whether the use of GLP-1 RAs alters food purchasing patterns among users.
The study analyzed survey data on GLP-1 adoption linked with detailed grocery and restaurant transaction records from a large, nationally representative household panel comprising approximately 150,000 U.S. households. The analysis focused on changes in food spending following the initiation of appetite-suppressing GLP-1 medications. Households…
